Parexel

Parexel is an American biopharmaceutical company founded in 1982. Parexel, which until July 2021 was owned by the management company Pamplona Capital Management, is engaged in clinical trials to accelerate the approval process for drugs and provides other services for drug manufacturers. The company has a representative office in Russia - Parexel International LLC (Rus).

History

2021: Goldman Sachs and EQT bought Parexel for $8.5 billion

At the beginning of July, 2021 it became known that EQT and Goldman Sachs Asset Management (investment podrazdeleniyegoldman Sachs Group) buy the Parexel company which is engaged in clinical trials. The transaction amount is $8.5 billion.

Over the past 18 months, according to Parexel CEO Jamie McDonald, the company has continued to grow confidently, focusing on patients and accelerating the development of new therapies for needy patients worldwide.

Goldman Sachs and EQT acquired Parexel for $8.5 billion

Given that the market for outsourced clinical research services will grow with a conservative average annual growth rate of 8% to 9%, we remain focused on promoting and implementing Parexel innovations. EQT and Goldman Sachs support this vision and intend to invest in Parexel and our employees to capitalize on this exciting market opportunity and make a difference for the better for patients, he added.

Eric Liu, partner and co-head of EQT's global health division, noted that the company had been following Parexel for several years and was impressed with the company's development and trajectory. EQT's investment in Parexel, he said, reflects EQT's thematic focus on the life sciences industry, as well as the company's commitment to partnering with businesses that have a positive impact on society.

We are pleased to partner with Goldman Sachs in the next phase of Parexel's journey and support Jamie, who until his position at Parexel has long been a senior adviser to EQT, Liu noted.[1]

Notes